RT Journal Article
SR Electronic
T1 Using next generation matrices to estimate the proportion of infections that are not detected in an outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.24.21252339
DO 10.1101/2021.02.24.21252339
A1 H Juliette T Unwin
A1 Anne Cori
A1 Natsuko Imai
A1 Katy A. M. Gaythorpe
A1 Sangeeta Bhatia
A1 Lorenzo Cattarino
A1 Christl A. Donnelly
A1 Neil M. Ferguson
A1 Marc Baguelin
YR 2022
UL http://medrxiv.org/content/early/2022/03/03/2021.02.24.21252339.abstract
AB Contact tracing, where exposed individuals are followed up to break ongoing transmission chains, is a key pillar of outbreak response for infectious disease outbreaks. Unfortunately, these systems are not fully effective, and infections can still go undetected as people may not remember all their contacts or contacts may not be traced successfully. A large proportion of undetected infections suggests poor contact tracing and surveillance systems, which could be a potential area of improvement for a disease response. In this paper, we present a method for estimating the proportion of infections that are not detected during an outbreak. Our method uses next generation matrices that are parameterized by linked contact tracing data and case line-lists. We validate the method using simulated data from an individual-based model and then investigate two case studies: the proportion of undetected infections in the SARS-CoV-2 outbreak in New Zealand during 2020 and the Ebola epidemic in Guinea during 2014. We estimate that only 5.26% of SARS-CoV-2 infections were not detected in New Zealand during 2020 (95% credible interval: 0.243 – 16.0%) but depending on assumptions 39.0% or 37.7% of Ebola infections were not detected in Guinea (95% credible intervals: 1.69 – 87.0% or 1.7 – 80.9%).Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledge funding by Community Jameel. HJTU also acknowledges funding from Imperial College, London for her fellowship. CAD also acknowledge the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None requiredI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used is included in the paper and code can be found at https://github.com/mrc-ide/MissingCases. https://github.com/mrc-ide/MissingCases